Development status · reviewed 11 Sep 2026

Evidence & status

Strong preclinical proof-of-concept · Research Use Only

We publish our claims only as far as the evidence goes. This page states, plainly, where the programme stands after UL BIO's internal scientific council review of 11 September 2026.

Where the evidence stands

• Results to date are internal and described in a patent application.
• They have not yet been peer-reviewed, independently replicated, or audited by a third party.

Demonstrated in the reviewed evidence

• AdMSC → hematopoietic conversion route - defined conversion workflow, culture and expansion steps.
• No-exogenous-gene route - supported by the patent-described embodiment; the route does not first convert the cells into induced pluripotent stem cells (iPSCs).
• Human HSPC-associated phenotype - CD34, CD90, CD49f positive.
• Human erythroid-lineage output - CD235a and fetal-Hb positive (partial).
• Mouse multilineage-associated output - donor-associated erythroid / platelet / leukocyte markers.
• Mouse in-vivo donor-derived contribution - significant supporting evidence.

Not yet proven or verified

• Bona fide human LT-HSC identity - no durable human multilineage repopulation and self-renewal shown.
• Human long-term engraftment - no audited long-term chimerism dataset.
• Secondary transplantation / self-renewal - no definitive serial-transplant evidence.
• Donor-to-donor and batch / operator reproducibility - not yet verified; run-level datasets being reconstructed.
• Customer workflow utility and clinical utility - not proven; clinical claims are out of current scope.

Boundaries we hold

• The 11.7% figure is a mouse cell-population value, not a confirmed human conversion efficiency.
• "18 months" is 4 of 6 recipient mice reported healthy at 18 months - not 18-month durable engraftment.
• The mouse transplant mixed converted cells with bone-marrow cells, so it does not show our cells alone reconstitute blood formation.
• Lineage markers do not equal mature, functional, transfusion- or therapy-grade blood cells.

Our rule

Never upgrade a marker, survival observation, patent narrative or project slide into a stronger biological claim than the underlying assay directly supports. Public claims on this site change only when new primary evidence materially moves one of these gates.